Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Tebipenem Pivoxil Hydrobromide Formulations
NCT04421885Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Jun 2020
- Primary completion
- Jul 2020
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tebipenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (3 arms), sponsored by Spero Therapeutics. Primary endpoints: Area under the curve extrapolated to infinity, Area under the concentration-time curve from time 0 to last observed concentration and 1 more. Started Jun 2020; status: completed.
02
Drugs
tebipenem
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT04421885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04421885.